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Abstract
Background: MicroRNAs (miRNAs) are noncoding RNA molecules heavily involved in human tumors, in which few
of them circulating the human body. Finding a tumor-associated signature of miRNA, that is, the minimummiRNA
entities to be measured for discriminating both different types of cancer and normal tissues, is of utmost importance.
Feature selection techniques applied in machine learning can help however they often provide naive or biased results.
Results: An ensemble feature selection strategy for miRNA signatures is proposed. miRNAs are chosen based on
consensus on feature relevance from high-accuracy classifiers of different typologies. This methodology aims to
identify signatures that are considerably more robust and reliable when used in clinically relevant prediction tasks.
Using the proposed method, a 100-miRNA signature is identified in a dataset of 8023 samples, extracted from TCGA.
When running eight-state-of-the-art classifiers along with the 100-miRNA signature against the original 1046 features,
it could be detected that global accuracy differs only by 1.4%. Importantly, this 100-miRNA signature is sufficient to
distinguish between tumor and normal tissues. The approach is then compared against other feature selection
methods, such as UFS, RFE, EN, LASSO, Genetic Algorithms, and EFS-CLA. The proposed approach provides better
accuracy when tested on a 10-fold cross-validation with different classifiers and it is applied to several GEO datasets
across different platforms with some classifiers showing more than 90% classification accuracy, which proves its
cross-platform applicability.
Conclusions: The 100-miRNA signature is sufficiently stable to provide almost the same classification accuracy as the
complete TCGA dataset, and it is further validated on several GEO datasets, across different types of cancer and
platforms. Furthermore, a bibliographic analysis confirms that 77 out of the 100 miRNAs in the signature appear in lists
of circulating miRNAs used in cancer studies, in stem-loop or mature-sequence form. The remaining 23 miRNAs offer
potentially promising avenues for future research.
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Background
Cancer is difficult to diagnose and classify at early stages,
and is one of the top leading causes of death worldwide
[1]. Therefore, several attempts have been made to iden-
tify possible biomarkers for cancer detection. MicroRNAs
(miRNAs) represent a class of small noncoding RNA
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molecules, with a critical role in the post-transcriptional
regulation of gene expression. miRNAs also act on several
cellular processes, such as cell differentiation, cell cycle
progression, and apoptosis. Additionally, in tumors, some
miRNAs can function as oncogenes, while others suppress
tumors [2]. Succeeding the earliest evidence of miRNA
involvement in human cancer by Croce et al. [3], various
studies have demonstrated that miRNA expressions are
deregulated in human cancer through a variety of mech-
anisms [4]. Since ectopic modulation of specific miRNAs
compromise the hallmarks of cancer, several efforts have
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been spent to generate scaffold-mediated miRNA-based
delivery systems trying to demonstrate the potential of
miRNA-mediated therapies.
In comparison to invasive methods currently used for
cancer diagnosis, there is an ongoing debate on the use of
circulating miRNAs as possible biomarkers due to the fact
that they can be detected directly from biological fluids,
such as blood, urine, saliva and pleural fluid [5]. MiRNAs
possess other qualities of good candidate biomarkers such
as: a) they are useful for the identification of cancer types,
b) their availability of high-quality measurement tech-
niques for miRNAs and c) they present good conservation
between practical and preclinical models [6].
Several studies have shown the properties of miRNAs as
oncogenes and tumor suppressors genes [7–9]. Since then,
techniques such as microarray (Affymetrix, Agilent) and
sequencing techniques (Illumina), have been proposed for
their identification [10]. In the context of increasing avail-
ability of data, it is of utmost practical importance to build
databases of miRNA expressions data for cancer research
[11–13] and to extract features that could be used as
cancer biomarkers [14–16]. For example, the expression
levels of miRNA hsa-miR-21 change for different cancer
types such as: squamous cell lung carcinoma [17], astro-
cytoma [18], breast cancer [19], and gastric cancer [20].
Following this idea, the scientific community is currently
looking for miRNA signatures (a subset of miRNAs), rep-
resenting the minimal number of miRNAs to be measured
for discriminating between different stages and types of
cancer.
Thousands of miRNAs have been identified, and
currently miRBase (v22.1) contains 1917 stem-loop
sequences, and 2657 mature sequences for human
microRNA [13]. Although a classification of cancer tumor
type is possible using isomirs [21], not all of the miRNAs
listed are available in every study, and only a few of them
have been shown to work as circulating biomarkers [6].
Obtaining a minimal list of miRNAs able to correctly clas-
sify tumors is of utmost practical importance, because it
would reduce the measurements needed and improve the
likelihood of validation across multiple studies.
Several approaches in the literature propose the use of
machine learning techniques for feature selection involv-
ingmiRNAs. For example, feature selection for identifying
miRNA targets [22], for prediction of specific biomarkers
for tumor origin [23] and to learn subset of features for
tumor classification [24]. In this study, the objective was
to use feature selection and to uncover a small miRNAs
signature with the aim to correctly classify cancer tumor
types, and distinguish between normal and tumor tissue
reducing the necessary features by an order of magnitude.
We propose an ensemble feature selection method,
starting from a subset of The Cancer Genome Atlas
dataset (TCGA) [25], containing 8023 cases, with 28
different types of cancer, and 1046 different stem-
loop miRNA expressions (miRBase V161, summarized in
Table 10). Typically, classifiers trained on a dataset do
not use the whole set of available features to separate
classes, but only a subset which could be ordered by rel-
ative importance, with a different meaning given to the
list by the specific technique, pushing for simpler mod-
els. Using 8 state-of-the-art classifiers implemented in the
scikit-learn toolbox [26], the most relevant miRNAs
are extracted to be used as features for cancer classifica-
tion. The top k features in the list are then evaluated as a
potential reduced signature for classification. In this work,
after preliminary tests, we select k = 100 to reduce the
original features by an order of magnitude. Because other
feature selection methods require the user to specify a
desired number of features, this also allows for a fair and
meaningful comparison with these methods.
The obtained 100-miRNA signature is first tested to
classify the initial TCGA dataset, and later applied on
14 Gene Expression Omnibus (GEO) datasets obtained
with different platforms (Affymetrix Multispecies Array
miRNA-1, miRNA-2 and miRNA-3, Illumina 2000, and
Agilent-021827 Human miRNA Microarray V3), for
different cancer tumor types (Prostate, Liver, Breast,
Esophageal, Head and Neck Squamous and Lung). A
summary of this validation is presented in Fig. 1. Further-
more, the proposed methodology is compared to popular
feature selection methods in bioinformatics, such as Uni-
variate Feature Selection, Recursive Feature Elimination,
Genetic Algorithms, Least Absolute Shrinkage and Selec-
tion Operator, Random Selection, Elastic Net and Ensem-
ble Feature Selection with Complete Linear Aggregation.
Next, we use the same signature to try to distinguish
molecular subtypes in breast cancer, both for the TCGA
dataset and a set of GEO datasets. Finally, the 100 miR-
NAs included in the signature are evaluated through a
meta-analysis based on the medical literature. Because
this meta-analysis reveals known relationships between
features selected by our approach, relative to the type of
cancer considered, it has the potential to yield insight
into the biological processes and relationships combinedly
affecting miRNAs and cancer.
Results
Feature selection and validation on the tCGA dataset
Table 1 compares the classification accuracy on a 10-
fold cross-validation for each classifier, using the full 1046
features, and then employing the reduced 100-miRNA sig-
nature. It is interesting to notice how the accuracy is, for
most cases, unchanged, providing empirical evidence that
a 100-miRNA signature is enough to obtain good classifi-
cation results, with a small statistically significant (T-test,
p < 0.05) difference of 1.4%.
1ftp://mirbase.org/pub/mirbase/16/
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Fig. 1 Summary of the different datasets and their use in the experiments
Figure 2 shows a heatmap comparing the relative fre-
quency of the overall top 100 most frequent miRNA
features, for each considered classifier. As expected, not
all classifiers used the same features to separate the types
of cancer, and thus, evaluating their consensus is more
robust than just relying upon a single algorithm, as it is
commonly accepted in the field of machine learning [27].
It is interesting to notice that while the most common
biomarkers appear among the top for most classifier,
others make use of only a few. For example, Bagging
and Ridge do not use the vast majority of the features
exploited by other techniques to discriminate between
classes. A further difference between the two classifiers
is that features used by Bagging that also appear in the
top 100 are clearly important for the classifier, being used
in almost 100% of its 10 runs; while it is noticeable how
Table 1 Accuracy of classifiers used in the experiments on the TCGA dataset
Classifier Accuracy (10-fold CV)
1046 Features 100 Features Hyper parameters Feature selection method
avg std avg std
Gradient Boosting 0.9398 0.0076 0.9359 0.0086 300 predictors Decision Trees
Random Forest 0.9351 0.0071 0.9324 0.0073 300 predictors Decision Trees
Logistic Regression 0.9178 0.0096 0.9237 0.0067 - Coefficients
Passive Aggressive 0.9117 0.0104 0.8831 0.0115 - Coefficients
SGD 0.91 0.0074 0.9035 0.0152 - Coefficients
SVC 0.9211 0.0122 0.9154 0.0065 Linear kernel Coefficients
Ridge 0.8971 0.0138 0.8305 0.0062 - Coefficients
Bagging 0.9151 0.0120 0.9110 0.0077 300 predictors Decision Trees
Average 0.918463 - 0.9044 - - -
In the case a classifier is not using standard values for its hyperparameters, the relevant variations are summarized in the corresponding column
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Fig. 2 Heatmap with the frequency of the overall top 100 most frequent features, divided by classifier. Features are sorted from overall most to least
frequent, from left to right, using information from the whole ensemble. For example, the most frequent is mir-10b, that is considered important by
all classifiers. Color intensity is computed using information from instances of the same classifier, only. This shows the different importance that
different classifiers assign to each feature
Ridge probably bases its discrimination on features that
do not appear among the top 100. This would also explain
why Ridge is the only algorithm that presents a decrease
in performance when using the 100-miRNA signature. It’s
important to note that, while the results emerging from
the heatmap suggest that this is indeed the case, Ridge’s
decision boundaries should be analyzed more in-depth,
for each class and multiple instances, in order to have
absolute certainty, a task that is outside of the scope of
the current work. Figure 3 shows the difference between
1046 features and 100 features for each cancer type and
classifier.
Fig. 3 Heatmap of the accuracy by cancer type, by classifier using the 1046 features (top) and the 100-miRNA signature (bottom)
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Normal vs tumor tissue classification
We compared Tumor Tissue (TT) vs Normal Tissue
(NT) in a 10-cross fold validation, using stratified cross-
validation to maintain the proportions for the two classes
inside the folds. The global score and the classification
accuracy by class are reported in Table 2. All of the clas-
sifiers have fair quality for differentiating between normal
tissue and tumor tissue, except Ridge, which is more
sensitive to the unbalanced number of examples.
Comparison to established feature selection methods
Several feature selection techniques have been proposed
for microarray data [28]. The most effective approaches
includeUnivariate Feature Selection (UFS), Recursive Fea-
ture Elimination (RFE), Elastic Net (EN), Genetic Algo-
rithms (GALGO), Least Absolute Shrinkage and Selection
Operator (LASSO) and Ensemble Feature Selection with
Complete Linear Aggregation (EFS-CLA). UFS aims at
finding the best features, scoring them using univari-
ate statistical tests, such as the ANOVA F-value [29],
and ultimately taking the k features with the highest
scores. RFE runs several times a machine learning algo-
rithm capable of scoring features, such as SVC, iteratively
removing the feature with the lowest score [30] until it
reaches the user-specified k features. EN simply runs the
machine learning algorithm Elastic Net [31], and takes
the k highest-scored features. As Elastic Net is trying
to balance accuracy and weight size in a linear model,
exploiting L1 and L2 regularization, it is a popular choice
for feature selection in bio-informatics [32, 33], because it
tends to create sparse models with few weights different
from zero. LASSO is a regression analysis method, per-
forming variable selection and regularization to improve
prediction accuracy and interpretability of the statisti-
cal model it produces [34], so it can be easily used
for feature selection, only. All considered feature selec-
tion methods are implemented in the machine learning
package scikit-learn, already used in the previous
experiments. GALGO is a genetic algorithms-based fea-
ture selection library in R that ranks the features using
several calls to a classifier and choosing the features that
appear the most after evolving a subset several times [35].
EFS-CLA is a method that uses instances of SVM with
several calls to a subsample of the data, ranks the fea-
tures by weight value and reduces a percentage at each
iteration [36].
As some of these techniques require the user to spec-
ify the number of features k to be taken, to provide a
comparison with the approach presented in this paper,
we have selected k = 100 features using all the for-
merly described feature selection methods and compared
classification accuracy on the considered classifiers with
a 10-fold cross validation. For RFE, we have decided to
use SVC, as not only it is commonly adopted for feature
selection in bioinformatics [30, 37], but also represents a
good compromise between accuracy and speed of con-
vergence on our specific dataset. For EN, we have chosen
the ElasticNetCV scikit-learn method, which exploits
a 3-fold cross-validation to automatically adapt the inter-
nal parameter α, balancing the importance of L1 and L2
regularization in the model. For the same reasons, the
LassoCV scikit-learn method is selected for LASSO. For
EFS-CLA, we use percentage of reduction E = 20%, 40 as
SVM calls per step, and k=100. Finally, we add a random
selection of 100 features, as a baseline reference to portray
the efficiency of the feature selection algorithms.
From the results presented in Table 3, it is immedi-
ately clear that the 100 features selected by UFS are much
less informative than the ones found by the proposed
approach. RFE performs better, especially when consider-
ing SVC as the classifier used for the cross validation, but
overall the performance for the other classifiers is lower. It
must also be noted that, among all the methods, RFE is the
most computationally expensive, as it calls the considered
classifier, SVC in this case, N − k = 1, 046 − 100 = 946
times, where N is the original number of features. All
feature selection algorithms, as expected, perform much
better than the baseline random selection of features.
A qualitative analysis of the features selected by each
method shows that the highest-scoring ones are easily
Table 2 Accuracy for each classifier in a 10-fold cross-validation for the comparison between Tumor Tissue (TT) and Normal Tissue (NT)
for 1046 and 100 features
Classifier 100-NT 100-TT 1046-NT 1046-TT 100-Global 1046-Global
Gradient Boosting 0.8612 0.9944 0.8707 0.9950 0.9846 0.9859
Random Forest 0.8091 0.9978 0.7256 0.9985 0.9839 0.9785
Logistic Regression 0.8423 0.9908 0.8659 0.9764 0.9799 0.9683
Passive Aggressive 0.7177 0.9798 0.8123 0.9728 0.9606 0.9611
SGD 0.8060 0.9902 0.7445 0.9936 0.9767 0.9754
SVC(linear) 0.8517 0.9892 0.8218 0.9771 0.9791 0.9657
Ridge 0.2997 0.9981 0.5994 0.9923 0.9470 0.9635
Bagging 0.8028 0.9953 0.7792 0.9966 0.9812 0.9807
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Table 3 Comparison between different feature selection techniques and the proposed ensemble method for k = 100, on the TCGA
dataset
Classifier Random GALGO EFS-CLA UFS EN LASSO RFE EFS
Gradient Boosting 0.8588 0.8782 0.8871 0.9028 0.9208 0.9315 0.9309 0.9359
Random Forest 0.8515 0.8787 0.8824 0.8929 0.9224 0.9341 0.9288 0.9324
Logistic Regression 0.8015 0.8295 0.8832 0.8813 0.8988 0.8996 0.9088 0.9237
Passive Aggressive 0.6986 0.7235 0.8111 0.8091 0.8406 0.8424 0.8506 0.8831
SGD 0.7278 0.764 0.8446 0.8334 0.8649 0.8648 0.8824 0.9035
SVC 0.8077 0.8348 0.8706 0.885 0.9049 0.9008 0.9103 0.9154
Ridge 0.6534 0.6614 0.7422 0.7504 0.7753 0.7751 0.7954 0.8305
Bagging 0.822 0.8382 0.8562 0.8719 0.8889 0.9078 0.9061 0.911
Global Average 0.7777 0.8010 0.8472 0.8534 0.8771 0.8820 0.8892 0.9044
Calls to Classifier - 60,000 480 - - 10 946 80
found by all considered approaches. In particular, from the
100 features found by our approach, 8 are in commonwith
Random, 11 with GALGO, 29 with EFS-CLA, 38 are com-
mon to the group obtained through UFS, 44 are shared
with the group found by LASSO, 48 again are found by
EN, and 54 are in common with RFE.
Cross-Platform validation on gEO datasets
As different datasets present distinctive sets of miRNAs,
it is important to assess the performance of the signature
we identified on unseen data. Using the methodology pre-
viously described, the proposed approach is validated on
the 14 GEO datasets. Each run of a classifier on a dataset
was repeated 10 times, to compensate possible random
elements that appear during the training phase of spe-
cific algorithms, e.g. RandomForest. It is worth noticing
how this validation presents considerable challenges. As
we are dealing with different platforms, not all of the 100
features in the signature were available everywhere. For
most GEO datasets 98 were available, while for GSE62182
featured 75 of them. Furthermore, despite the transforma-
tion needed to bring the samples of the GEO datasets in
the TCGA dataset space, samples measured by platforms
used in the GEO datasets might prove particularly dif-
ficult to tackle for classifiers trained on TCGA samples,
as most GEO datasets use microarray technology while
TCGA uses sequencing. The properties of the used GEO
datasets are summarized in Table 4.
Figure 4 shows the outcomes of the validation for all
classifiers. In spite of the difficulties, most algorithms
yielded good classification results, with Logistic and
SGD in particular featuring over 93% average accuracy on
all GEO datasets. Several classifiers, on the other hand,
show poor performance on specific datasets, probably
Table 4 Summary of the used GEO datasets, and the number of features in common with our 100-miRNA signature
Dataset ID Platform Tumor Type #Samples Total Feats. Common Feats. Reference
GSE34496 GPL8786 HNSC 44 847 98 -
GSE36802 GPL8786 PRAD 21 847 98 [38]
GSE67138 GPL8786 LIHC 57 847 98 -
GSE67139 GPL8786 LIHC 115 847 98 -
GSE45604 GPL14613 PRAD 50 2143 98 [39]
GSE48088 GPL14613 BRCA 33 2143 98 [40]
GSE55856 GPL14613 ESCA 108 2143 98 [41]
GSE86277 GPL14613 BRCA 72 2143 98 [42]
GSE116182 GPL14613 LIHC 64 2143 98 -
GSE86278 GPL16384 BRCA 49 3,242 98 [42]
GSE86281 GPL16384 BRCA 50 3,242 98 [42]
GSE31164 GPL10850 LIHC 110 851 98 [43]
GSE105134 GPL10850 BRCA 50 851 98 -
GSE62182 GPL11154 LUAD 94 3,242 75 [44]
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Fig. 4 Results with the 100 selected features in the GEO datasets, using a 10-fold cross-validation. From the average accuracy and standard
deviation, SGD proves to be significantly better than the rest using a Kolmogorov-Smirnov test (p < 0.05)
due to the way their decision boundaries for that specific
class were learned on the TCGA dataset. In this sense,
dataset GSE45604 proves to be the overall hardest to clas-
sify correctly for most algorithms. GSE86277,GSE86278
and GSE86281, deal with different molecular subtypes of
BRCA, that could explain some of the performance issues.
Finally the average performance in GSE62182, is because
the classifiers have problems differentiating LUAD and
LUSC. In general, however, different algorithms seem to
have difficulties for different classes and datasets, which
suggests that an ensemble approach for classification
could compensate local issues.
To the best of our knowledge, the most similar work
in literature that we can compare our results to is Telo-
nis et al. [21], where isoform quantification was adopted
to classify three of the GEO datasets used in this study
(GSE36802, GSE67138, GSE67139), training SVC on a
TCGA-derived dataset. For GSE36802, [21] reports an
accuracy of 76%, that is surpassed by all of the classifiers.
Considering GSE67138, for which an accuracy of 91% is
reported, all the algorithms in our case perform better.
Finally, for GSE67139, a 96% accuracy, again all the algo-
rithms outperform that value. It must be noted, however,
that even this comparison is made difficult by differences
in how data was treated: for example, [21] reduced the
number of classes to 6 and tested on 4 different types of
tumors. In our study, we keep all 28 classes for testing.
Tumor subtype
To further test our approach, we use the 100-miRNA sig-
nature to classify tumor subtypes. As a comparison with
GEO datasets is important for our validation, we select
molecular subtype in breast cancer (BRCA), as it’s the only
tumor class for which molecular subtype information is
available in the GEO datasets. From the information in
[45, 46], we are able to label 764 of the 777 BRCA sam-
ples in the TCGA dataset in 5 different subtypes (Luminal
A, Luminal B, Triple-negative/basal-like, HER2-enriched
and Normal-like). More information on the subtypes can
be found in [47]. Next, we calculate the accuracy in a 10-
fold cross validation for the 1046 TCGA features and the
100-miRNA signature, with results reported in Tables 5
and 6 respectively.
The best classification results are obtained for subtypes
Triple-Negative Breast Cancer (TNBC) and Luminal A
(LumA), due to the scarcity of samples for other sub-
types (especially Normal and Her2). Luminal B (LumB)
presents considerable similarities to LumA, and the clas-
sifiers have difficulty separating the two subtypes using
the data at our disposal. For these reasons, and the prac-
tical concern that TNBC is the subtype of BRCA with
the worst prognosis, we decide to tackle the issue as a
binary classification problem, separating TNBC from the
other classes. TNBC is a subtype of cancer where the cells
have tested negative for estrogen receptors (ER), hormone
epidermal growth factor receptor 2 (Her2), and proges-
terone receptors (PR). This subtype of cancer has limited
treatment options and poor prognosis, as hormone ther-
apies or targeted drugs do not work on it. Results of the
binary classification problem on TCGA are reported in
Table 7.
Table 5 Molecular subtype classification accuracy of Breast
Cancer for the 1046 features
Normal LumA LumB TNBC Her2 Global
#Samples 33 399 139 135 58 764
Gradient Boosting 0.1818 0.9348 0.5396 0.9333 0.5172 0.7987
Random Forest 0.0606 0.9724 0.4532 0.9630 0.0345 0.7657
Logistic Regression 0.1212 0.8747 0.5540 0.9259 0.4483 0.7606
Passive Aggressive 0.1515 0.8622 0.5612 0.9111 0.4483 0.7539
SGD 0.3030 0.9073 0.4604 0.9556 0.4655 0.7752
SVC 0.2727 0.8797 0.5252 0.9185 0.5345 0.7697
Ridge 0.1515 0.7293 0.4317 0.3704 0.2759 0.5524
Bagging 0.3333 0.9298 0.5108 0.9704 0.4310 0.7973
Average 0.1970 0.8863 0.5045 0.8685 0.3944 0.7467
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Table 6 Molecular subtype classification accuracy of Breast
Cancer for the 100 features
Normal LumA LumB TNBC Her2 Global
#Samples 33 399 139 135 58 764
Gradient Boosting 0.2424 0.9248 0.5324 0.9333 0.5517 0.7975
Random Forest 0.2121 0.9599 0.4029 0.9704 0.2069 0.7712
Logistic Regression 0.2727 0.8997 0.4892 0.9037 0.5517 0.7727
Passive Aggressive 0.3939 0.8546 0.4460 0.8667 0.5000 0.7358
SGD 0.4545 0.8897 0.4460 0.8444 0.4310 0.7475
SVC 0.5152 0.8446 0.5108 0.9037 0.5517 0.7581
Ridge 0.0606 0.9474 0.4388 0.8593 0.3966 0.7594
Bagging 0.2727 0.9173 0.4964 0.9481 0.3793 0.7777
Average 0.3030 0.9048 0.4703 0.9037 0.4461 0.7650
Finally, we test the binary subtype classification of
BRCA for the GEO datasets, using just the 100-miRNA
signature. We create a single dataset composed of 4 series
(GSE86281, GSE86277, GSE86278, GSE46823), with 2
classes: TNBC, featuring 139 samples, and all other
molecular subtypes (LumA, LumB, and Her2), with 32
samples in total. Using the stem-loop sequences from plat-
form GPL14613, and GPL1368, we use the 98 common
stem-loop miRNAs of the 100 in the signature signature
for the classification. In Table 8, we show the results of
the classification in a 10-fold cross validation, and the
accuracy by class.
Discussion
The results of the five experiments performed with the
100-miRNA signature (Tumor Type Classification, Tumor
Tissue vs Normal Tissue, GEO datasets, BRCA subtype in
TCGA, and BRCA subtype in GEO datasets), are reported
in Table 9. All classifiers show high levels of accuracy over
all trials, with the validation on the GEO datasets (both
tumor type and subtype classification) proving to be the
hardest task.
As miRNAs have been shown to regulate approximately
30% of the human genes, and because their dysregulation
has been associated with the development and progres-
sion of cancer, miRNAs have been found to have the
potential to play a critical role in computational oncol-
ogy. Nevertheless, their analysis and their employment
in clinically relevant settings still faces various, spe-
cific technical challenges: a) the extremely small size of
the miRNAs leads to diverse complications for exam-
ple with respect to hybridization techniques, b) there
is a lack of specificity in detection because of the high
similarity of several miRNA family members, and c)
the low expression of various miRNAs requires detec-
tion methods of utmost sensitivity [48]. To date, most
new miRNAs are discovered through cloning, despite
these methods being time-consuming, low-throughput,
and being biased toward the discovery of abundant
miRNAs [49, 50].
Nevertheless, we can conclude from our results that the
extracted 100-miRNA signature is able to reliably classify
the 28 different types of cancer in the TCGA dataset, and
distinguish between normal and tumor tissue. In addition,
it is sufficiently stable to be applicable across platforms,
such as the ones such as the ones used in the ten GEO
datasets and ahich show a good accuracy in differentiating
TNBC from other molecular subtypes of BRCA. Looking
ahead into the possibility of classifying tumor types using
miRNAs, we need to consider circulating miRNAs, and
their relationship to cancer studies.
For the miRNAs included in the signature, we per-
formed a bibliographic meta-analysis of specialized lit-
erature. The proposed meta-analysis is mainly based
on 5 surveys of circulating miRNAs for cancer studies
[6, 7, 51–53]. Out of the 100 miRNAs in the signature,
77 appear as circulatory miRNAs, either in their stem-
loop form or mature sequence. The complete list for the
100-miRNAs is reported in Annex A of the online Addi-
tional file 1, in Fig. 5 shows the expression levels by type
of cancer of the top 50 miRNAs.
Table 7 TNBC classification from the other molecular subtypes in the TCGA dataset, using 1046 features and 100 signature
TNBC-100 TNBC-1046 Other-100 Other-1046 Global-100 Global-1046
#Samples 135 135 629 629 764 764
Gradient Boosting 0.9111 0.8963 0.9857 0.9857 0.9725 0.9699
Random Forest 0.8889 0.8815 0.9905 0.9905 0.9725 0.9712
Logistic Regression 0.8963 0.9630 0.9793 0.9587 0.9647 0.9593
Passive Aggressive 0.8815 0.9630 0.9714 0.9523 0.9556 0.9540
SGD 0.8000 0.8222 0.9809 0.9841 0.9490 0.9555
SVC 0.8444 0.8963 0.9666 0.9825 0.9451 0.9673
Ridge 0.8000 0.7259 0.9825 0.9237 0.9503 0.8888
Bagging 0.8444 0.8963 0.9793 0.9825 0.9555 0.9673
Average 0.8583 0.8806 0.9795 0.9700 0.9582 0.9542
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Table 8 Molecular subtype classification of Breast Cancer to
separate TNBC from other breast cancer subtypes using the
100-miRNA signature, on the GEO dataset
TNBC Other Global
#Samples 139 44 183
Gradient Boosting 0.9353 0.7500 0.8909
Random Forest 0.9424 0.6136 0.8634
Logistic Regression 0.9065 0.6590 0.8476
Passive Aggressive 0.8561 0.7045 0.8197
SGD 0.9065 0.5227 0.8145
SVC 0.8561 0.7727 0.8355
Ridge 0.8993 0.6136 0.8300
Bagging 0.9496 0.7727 0.9070
Average 0.9065 0.6761 0.8511
Across all surveys analyzed, hsa-miR-21, included in our
signature in stem-loop form, appears to be the most com-
monly over-expressed miRNA for all classes of tumors,
as we would expect of a known oncomarker. In Annex
B of the Additional file 1, we present a detailed analysis
of the top 50 miRNAs in the signature, showing cancer
study type, reference and circulating sample type used for
measuring the expression. 23 miRNAs in the signature
do not appear in the surveys, but they are mentioned in
recent research papers, as promising research leads whose
role may need further corroboration (we put the mature
sequence as they appear in the study): miR-211 [54],
miR-135a [55],miR-3678-3p [56],miR-204 [57],miR-1228
[58], miR-374b [59], miR-424 [60] miR-217-5p [60] miR-
3613-5p [61], miR-124 [62], miR-1277-5p [63] miR-190
[64], miR-934 [65], miR-490 [66], miR-1247 [67], miR-
199b [68], miR-135a [55], miR-503 [69], miR-584 [70],
miR-137-3p [71], andmiR-103 [72].
Table 9 Comparison of the 8 classifiers, for the different
experiments with the 100-miRNA signature
TT vs TCGA GEO
Classifier TCGA NT GEO (Subtype) (Subtype) Global
Gradient Boosting 0.9359 0.9846 0.6697 0.9725 0.8909 0.8907
Random Forest 0.9324 0.9839 0.8085 0.9725 0.8634 0.9121
Logistic Regression 0.9237 0.9799 0.9351 0.9647 0.8476 0.9302
Passive Aggressive 0.8831 0.9606 0.8678 0.9556 0.8197 0.8974
SGD 0.9035 0.9767 0.9393 0.9490 0.8145 0.9166
SVC 0.9154 0.9791 0.7724 0.9451 0.8355 0.8895
Ridge 0.8305 0.9470 0.8867 0.9503 0.8300 0.8889
Bagging 0.9110 0.9812 0.7682 0.9555 0.9070 0.9046
Logistic Regression was the best across all experiments, and Ridge has the worst
accuracy
Interestingly, hsa-mir-135a-1 and hsa-mir-135a-2,
located inside chromosomes 3 and 12, respectively, gen-
erate the same mature active sequence [73]. In the same
manner, hsa-mir-124-1, hsa-mir-124-2, and hsa-mir-124-
3, generate the same mature sequence hsa-miR-124-5p,
and miR-124 is known as a tumor suppressor in head
and neck squamous cell carcinoma [74], hepatocellular
carcinoma [75] and breast cancer [76]. All of them were
identified by our feature selection approach, indicting
the presence of miRNA pathways shared across different
tumor types. Targeting these miRNA pathways with
anti-miRNA-based approaches such as infection with
viral particles (having antisense sequence against the
specific miRNA) or even drug design of small molecules
inhibitors of miRNAs (SMIRs) which can be considered
potential anti-tumoral therapy. On the other hand, the
down regulation of tumor suppressor miRNAs also
contributes to the acquisition of malignant features. For
example, by ectopic expression of hsa-miR-944 which
decreases malignant features in gastric [77], colorectal
[78] and endometrial [79] cancers. Strikingly, miR-
944 and other understudied miRNAs could have been
detected by our approach analizing 28 different types of
cancer, suggesting that they could play a key role in the
biology of cancer. Future works will include further analy-
ses of the 100-miRNA signature, crossing the information
with genetic sources, assessing measures of gene quality
and biomarker stability, using tools such as sigQC [80].
Conclusions
miRNAs fine-tune the regulation of the transcriptome
[81, 82]. Alterations in miRNA expression profiles are
associated with several diseases, such as cancer. On the
other hand, the alteredmiRNA expression profiles present
in cancer could be used as prognostic and/or diagnostic
markers. In summary, several miRNA signatures are asso-
ciated with clinically relevant factors [83, 84]. Therefore,
our miRNA signature, which we obtained by using data
from different types of cancers, can highlight the pres-
ence of so far underestimated miRNA’s such as miR-944,
and overall has the potential to be used in the frame of
microarray based assays, as a potential building block in
clinical decision support. Of course, further experimental
validation on cancer patient samples will be required to
weigh the biological significance of the signature in terms
of diagnosing, treating and prognosing the outcome of
cancer.
In this study, we developed a new machine-learning
approach to obtain a robust, reduced miRNA signature,
from a TCGA dataset containing 28 different types of can-
cer. When tested against other datasets, our system pro-
vided good classification accuracy using only the reduced
100-feature signature, despite significant differences in the
platforms used to gather the data. A further meta-analysis
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Fig. 5miRNAs mean expression levels (RPMs) of the top 50 miRNAs for each type of cancer tumor tissue
of literature on the miRNA in the identified signature
showed both well-known oncogenic and underestimated
miRNA types. The results of this work could potentially
be used to uncover new, promising leads of research for
a better understanding of miRNA behavior. Furthermore,
personal-directed anti-tumoral therapy could be achieved
by measurement of the specific, minimal miRNA signa-
ture, identified in this work.
Methods
Ensemble feature selection
As the objective is to discover and validate a reduced list of
miRNAs to be used as a signature for tumor classification,
we need to select features that could optimally assist in
distinguishing between different cancer types and tumor
tissue. In this sense, popular approaches used for feature
selection range from univariate statistical considerations,
to iterated runs of the same classifier with a progres-
sively reduced number of features in order to assess the
contribution of the features to the overall result. As the
considered problem is particularly complex, relying upon
simple statistical analyses might not suffice. Furthermore,
features extracted using an iterative method on one clas-
sifier are likely to work well only for that specific classifier.
Following the idea behind ensemble feature selection [36,
37, 85], we propose the use of multiple algorithms to
obtain a more robust and general predictive performance.
An ensemble approach has the advantage of obtaining fea-
tures that will be effective across several classifiers, with a
better likelihood of being more representative of the data,
and not just of the inner workings of a single classifier.
For this purpose, we train a set of classifiers in order
to extract a sorted list of the most relevant features from
each. Intuitively, as a feature considered important by the
majority of classifiers in the set is also likely to be rele-
vant for our objective, then information from all classifiers
is compiled to find the most common relevant features.
Starting from a comparison of 22 different state-of-the-art
classifiers on the considered dataset, presented in [86], a
subset of those classifiers was selected considering both;
high accuracy and a way to extract the relative importance
of the features from the trained classifier. After prelimi-
nary tests to set algorithms’ hyperparameters, 8 classifiers
were chosen, all featuring an average accuracy higher
than 90% on a 10-fold cross-validation: Bagging [87],
Gradient Boosting [88], Logistic Regression
[89], Passive Aggressive [90], Random Forest
[91], Ridge [92], SGD (Stochastic Gradient Descent on
linear models) [93], SVC ( Support Vector Machines Clas-
sifier with a linear kernel ) [94]. All considered classifiers
are implemented in the scikit-learn Python toolbox.
Overall, the selected classifiers fall into two broad
typologies: those exploiting ensembles of classification
trees [95] (Bagging, Gradient Boosting, Random
Forest), and those optimizing the coefficients of linear
models to separate classes ( Logistic Regression,
Passive Aggressive, Ridge, SGD, SVC ). Depend-
ing on classifier typology, there are two different ways
of extracting relative feature importance. For classifiers
based on classification trees, the features used in the splits
are counted and sorted by frequency, from the most to the
least common. For classifiers based on linear models, the
values of the coefficients associated to each feature can be
used as a proxy of their relative importance, sorting coef-
ficients from the largest to the smallest in absolute value.
As the two feature extraction methods return heteroge-
neous numeric values, only the relative sorting of features
provided by each classifier was considered. Furthermore,
we decide to extract the top 100 most relevant features as
a reduction of about an order of magnitude, so we assign
to each feature f a simple score sf = Nt/Nc, where Nt is
the number of times that specific feature appears among
the top 100 of a specific classifier instance, while Nc is
the total number of classifiers instances used; for instance,
a feature appearing among the 100 most relevant in 73%
of the classifiers used would obtain a score sf = 0.73.
We select 100 features because we wanted to compress
the dataset at least 90%, thus from 1046 we reduce it to
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100. In order to increase the generality of our results,
each selected classifier was run 10 times, using a 10-fold
stratified cross-validation, so that each fold preserves the
percentage of samples of each class in the original dataset.
Thus, Nc = 80 (8 types of classifiers, run 10 times each).
The complete procedure is summarized by Algorithm 1.
Different approaches to the aggregation of heterogeneous
feature importance from various sources are also possible
(see for example [36, 37, 85]), such as assigning to each
feature a weight proportional to its relative importance.
However, most alternatives would require adding and tun-
ing extra parameters, so we decided to opt for a simpler
approach.
TCGA dataset
The data was downloaded from the TCGA Data Portal2,
on September 1, 2016. The used data is miRNA-SEQ
Algorithm 1: Ensemble feature selection.
1 Normalize dataset on each of the F features, Divide
dataset in N folds, Select K classifiers, Choose the
number of features in the signature S;
2 for each fold n of N do
3 for each classifier k of K do
Train classifier kn on all folds minus n, using all
features;
Test classifier kn on fold n;
Obtain sorted list lkn of features from kn;
Assign weight wfnk to each f of the F features;
4 for each feature f of F do
if f is among the top S features in lkn then
wfnk = 1
else
wfnk = 0
5 Nc = N · K ;
6 for each miRNA feature f do
Nt = ∑Nn
∑K
k wfnk ;
sf = Nt/Nc;
7 Select S-feature signature, from features with highest
sf ;
8 for each fold n of N do
9 for each classifier k of K do
Train classifier kn on all folds minus n, using
signature;
Test classifier kn on fold n;
10 Compare performance of classifiers using all features
and signature;
2https://tcga-data.nci.nih.gov/docs/publications/tcga/
files (*.mirna.quantification.txt) a total of 1046 miRNA
expression features for each sample in format mirbase
V16 for stem-loop sequences3. We consider the read per
million (RPM) values in the file and we remove all of
the samples where the item does not meet the study
protocol as stated in the file annotations. In summary,
the dataset used in the following experiments includes
28 types of tumors, 1046 miRNA features, and 8023
patient samples. Information on the dataset is summa-
rized in Table 10. We standardized the data by removing
the mean and scaling to unit variance (specifying that
we had learned the standardization on the training set,
and applied it to the test set, so that knowledge of the
whole dataset did not bias the performance on the test
set). In addition, we created a second dataset that dif-
ferentiates between normal tissue (NT) and tumor tis-
sue (TT) that consists of 8657 samples; 8023 TT and
634 NT.
Geo datasets
To validate our results, we use 14 datasets from the GEO
repository4, from 5 different platforms. We use 2 types of
miRNA discovery technologies: microarrays and sequenc-
ing. miRNAs expression levels are platform and technol-
ogy dependent [96–98]. Therefore, we need to consider
if the information is in stem-loop or mature sequence
and then calculate the contributions to make a direct
comparison.
In the TCGAdataset, stem-loop sequences were directly
measured in raw read counts. When reading a mature
sequence, the protocol that was followed assigns a read
count to it, and then randomly assigns a read count to one
of the stem-loop sequences that share the same mature
sequence [99].
GPL8786, gPL10850
Affymetrix Multispecies miRNA-1 Array (GPL8786)
and Agilent-021827 Human miRNA Microarray V3
(GPL10850) cannot read stem-loop sequences, so the
corresponding GEO datasets only show information for
mature sequences. Thus, in order to perform a fair com-
parison, we consider the raw read count for stem-loop
sequences as a linear function of the read counts of the
mature sequences. If we call the read counts of a spe-
cific stem-loop sequence Xi, for hsa-mir-10b we have for
example:
Xhsa−mir−10b = a0 ·Xhsa−miR−10b +a1 ·Xhsa−miR−10b∗ (1)
Where a0 and a1 are two coefficients to be set. Themap-
ping between the values of two different platforms P1 and
P2 can then be written as:
3ftp://mirbase.org/pub/mirbase/16/genomes/hsa.gff
4https://www.ncbi.nlm.nih.gov/gds
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Table 10 Summary of the TCGA dataset used in the study
Tumor Type Acronym Tumor Tissue Normal Tissue Class
Adrenocortical carcinoma ACC 80 0 0
Bladder Urothelial Carcinoma BLCA 411 19 1
Breast invasivex carcinoma BRCA 777 87 2
Cervical squamous cell carcinoma CESC 306 3 3
Cholangiocarcinoma CHOL 36 9 4
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma DLBC 47 0 5
Esophageal carcinoma ESCA 187 13 6
Head and Neck squamous cell carcinoma HNSC 487 44 7
Kidney Chromophobe KICH 66 25 8
Kidney renal clear cell carcinoma KIRC 260 71 9
Kidney renal papillary cell carcinoma KIRP 291 34 10
Lower Grade Glioma LGG 528 0 11
Liver hepatocellular carcinoma LIHC 374 50 12
Lung adenocarcinoma LUAD 458 46 13
Lung squamous cell carcinoma LUSC 341 45 14
Mesothelioma MESO 86 0 15
Pancreatic adenocarcinoma PAAD 154 4 16
Pheochromocytoma and Paraganglioma PCPG 184 3 17
Prostate adenocarcinoma PRAD 494 52 18
Sarcoma SARC 260 0 19
Skin Cutaneous Melanoma SKCM 450 2 20
Stomach adenocarcinoma STAD 399 45 21
Testicular Germ Cell Tumors TGCT 156 0 22
Thyroid carcinoma THCA 513 59 23
Thymoma THYM 124 2 24
Uterine Corpus Endometrial Carcinoma UCEC 417 21 25
Uterine Carcinosarcoma UCS 57 0 26
Uveal Melanoma UVM 80 0 27
Total 8023 634
Fig. 6 Example of mapping GSE microarray data into TCGA space (GSE36802)
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Fig. 7 Examples of PCA projections of GEO datasets transformed into the TCGA dataset space. Orange data points represent samples from the
target class from the TCGA dataset, the blue data points are other samples in TCGA, and the red points are the projected samples from GEO datasets
Lopez-Rincon et al. BMC Bioinformatics          (2019) 20:480 Page 14 of 17
XP1hsa−mir−10b = a2 · XP2hsa−mir−10b (2)
To reduce the problem, we consider only relationships
between a stem-loop sequence and its most common
corresponding mature sequence e.g hsa-mir-10b to hsa-
miR-10b, disregarding hsa-miR-10b*. From Eq. 1 and 2 we
then have:
XP1hsa−mir−10b = a2 · XP2hsa−mir−10b
XP1hsa−mir−10b = a2 ·
(
a0 · XP2hsa−miR−10b + a1 · XP2hsa−miR−10b∗
)
XP1hsa−mir−10b = a2 · a0 · XP2hsa−miR−10b
XP1hsa−mir−10b = aPhsa−miR−10b · XP2hsa−miR−10b
where aPi becomes the only coefficient to be found, and
it represents the transformation between platforms for
that specific sequence. A different linear function will be
found for each pair of platforms, as we assume that each
machine will have unique properties.
For GPL8786 GEO datasets, we consider the linear gene
expression values given by the function rmasummary
from the Matlab bioinformatics toolbox, which is a nor-
malized robustmulti-array average procedure, as a z-score
[100, 101]. The equation of a z-score is:
Z = (X − μ)
σ
(3)
where X is the value of a feature; μ and σ are the average
and the standard deviation for a feature. Next, by consid-
ering the linear expression values as z-scores, the GEO
datasets are mapped to corresponding intensities in the
TCGA dataset space, by solving for X:
Xi =
(
Zi ·
(
σTCGAi
)
+ μTCGAi
)
· aPi (4)
where Xi is the intensity of miRNA i in the TCGA dataset
space, Zi is the linear gene expression value given by
the scaled rmasummary summary function, μTCGAi and
σTCGAi are the average value and the standard deviation
for miRNA i, both computed on the original TCGA
dataset, and aPi is a scale value, dependent on the platform.
The value aPi is computed using a subset of all the GEO
datasets from the same platform, by minimizing the error
between actual class and predicted class, using a model
trained in the TCGA dataset with Root Mean Squared
Error (RMSE).
RMSE =
√
∑S
s=1 Predicteds
(
TCGA, aP
) − Actuals(TCGA)
S
(5)
where S is the total number of samples in the dataset, and
aP is a vector containing the values of aPi for each feature
i. A state-of-the-art numerical optimizer [102] is applied
to this task, to find the 98 parameters represented by aP.
For GPL10850 we use the MatLab function agferead
from the Bioinformatics Toolbox and use the value of
gTotalGeneSignal as value for each of the probes and
calculate the contributions and aPi as for GPL8786.
GPL14613, gPL16384
AffymetrixMultispecies miRNA-2 Array (GPL14613) and
Affymetrix Multispecies miRNA-3 Array (GPL16384)
measure the stem-loop sequences directly, and denote
them by hp_hsa. The linear relationship between the
TCGA dataset and the corresponding subset of GEO
datasets is thus represented by Eq. 2, and the aPi parame-
ters to be found are reduced to the a2i
As remarked by Telonis et al. [21], for these datasets,
not all the types of cancer are available, or present the
necessary quality standards. Thus, we reduce our analy-
sis to 6 different types of cancer; Prostate, Liver, Breast,
Esophageal, Head and Neck Squamous Cell and Lung.
For the sequencing data, extra mapping is not necessary
besides the sample normalization (platform GPL11154),
and we use only stem-loop sequences.
Using this procedure, we are able to map the GEO
repository measurements into the TCGA dataset space
as seen in Fig. 6. Other examples are shown in Fig. 7,
where plots were created using the first two dimensions
of a Principal Component Analysis (PCA) computed on
the TCGA dataset and applied to the GEO datasets, to
provide a comparison between the cancer type in each
GEO and the corresponding class in TCGA. Remarkably,
samples from GEO datasets are often considerably close
to samples of the corresponding class in TCGA. Dur-
ing validation, we selected the common features between
each GEO dataset and the 100-miRNA signature obtained
using the ensemble approach. The accuracy of the classifi-
cation algorithms was then evaluated by training them on
the TCGA dataset and testing them on each GEO dataset.
A summary of the experiments is presented in Fig. 1.
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